RYTM - Rhythm Pharma: Investible Based On Upcoming Trial Data
Rhythm Pharma (RYTM) is a relatively underfollowed company with an ongoing phase 3 trial of lead (and only) drug setmelanotide in two obesity-related syndromes, Bardet-Biedl Syndrome ((BBS)) and Alström Syndrome, where enrollment will be completed in late 2019, and two other genetic obesity syndromes, Leptin Receptor Deficiency Obesity (LEPR) and POMC deficiency obesity, where phase 3 data will be out by 2019.
Setmelanotide targets the MC4 pathway, which regulates weight by increasing metabolism and reducing appetite. When this pathway is affected by genetic mutations, it can lead to its malfunction, causing early onset